Overview

A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to estimate the rate of response for patients with ovarian, non-small cell lung, prostate, colorectal, gastroesophageal, and head and neck cancers who are administered LY2523355.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company